LON:SCLP

Scancell (SCLP) Share Forecast, Price & News

GBX 15.50

0.00 (0.00%)

(As of 06/5/2023 ET)

Compare

Today's Range: 15.37
▼
15.66
50-Day Range: 14.25
▼
20.50
52-Week Range: 10.75
▼
29.40

Volume: 199,193 shs
Average Volume: 761,369 shs
Market Capitalization: £126.85 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Chart Competitors Insider Trades Headlines

About Scancell (LON:SCLP) Stock

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, an ImmunoBody cancer vaccine for the treatment of metastatic melanoma; SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumours, including non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.

Receive SCLP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scancell and its competitors with MarketBeat's FREE daily newsletter.

SCLP Stock News Headlines

June 2, 2023 | proactiveinvestors.com

Scancell updates on progress ahead of ASCO poster presentation

April 18, 2023 | proactiveinvestors.com

Scancell says its Head of Clinical Operations to make AACR poster presentation

June 6, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

April 16, 2023 | americanbankingnews.com

Scancell (LON:SCLP) Stock Crosses Below 200-Day Moving Average of $19.25

March 13, 2023 | proactiveinvestors.com

Scancell has no exposure to Silicon Valley Bank, company assures stakeholders

March 13, 2023 | proactiveinvestors.com

Scancell Holdings had no exposure to Silicon Valley Bank, company assures stakeholders

February 13, 2023 | proactiveinvestors.com

Scancell Holdings hails as 'highly encouraging' the results from phase I Covid study

February 13, 2023 | proactiveinvestors.com

Scancell hails as 'highly encouraging' the results from phase I Covid study

June 6, 2023 | UNKNOWN (Ad)

Lithium Has Boomed And This American Stock Is Ready..

Lithium Has Been On A Crazy Rally Over The Last 3 Year's And This Stock Could Be Next!

February 1, 2023 | proactiveinvestors.com

Scancell announces appointment of Dr Jean-Michel Cosséry as its non-executive chairman with immediate effect

January 27, 2023 | finance.yahoo.com

Even though Scancell Holdings (LON:SCLP) has lost UK£33m market cap in last 7 days, shareholders are still up 217% over 3 years

January 25, 2023 | proactiveinvestors.com

Scancell hails period of clinical and commercial progress

January 22, 2023 | finance.yahoo.com

Scancell Holdings plc (SCLP.L)

December 10, 2022 | msn.com

Is the Scancell share price set to rocket in 2023?

December 7, 2022 | uk.finance.yahoo.com

Why is the Scancell share price climbing?

October 26, 2022 | proactiveinvestors.com

Scancell executive chairman John Chiplin to step down

October 26, 2022 | proactiveinvestors.com

Scancell says executive chairman John Chiplin to step down

October 25, 2022 | proactiveinvestors.com

Scancell signs exclusive deal with cancer giant Genmab for anti-glycan antibody

October 17, 2022 | yahoo.com

South Korea kicks off military drills amid talk of North Korean nuclear test - Yahoo! Voices

October 17, 2022 | finance.yahoo.com

Hedge funds investors own a significant stake of 44% in Scancell Holdings plc (LON:SCLP)

October 13, 2022 | streetinsider.com

NAV Update - StreetInsider.com

September 23, 2022 | proactiveinvestors.com

Scancell to provide new insights on its monoclonal antibodies technology - Proactive Investors USA

June 23, 2022 | proactiveinvestors.com

Scancell targets emerging class of cancer treatment with latest addition to pipeline

June 16, 2022 | proactiveinvestors.com

Scancell Holdings expands its phase II trial of cancer drug SCIB1

June 15, 2022 | marketscreener.com

FTSE 100 Closed Higher on Expected Rise in Fed Interest Rates - Marketscreener.com

June 15, 2022 | marketscreener.com

Sterling Could Fall After BOE Decision - Marketscreener.com

June 15, 2022 | morningstar.com

FTSE 100 Seen Higher With Fed Rate Decision In Focus - Morningstar

See More Headlines

SCLP Price History

30 days | 90 days | 365 days | Advanced Chart

SCLP Company Calendar

Last Earnings: 1/31/2020
Today: 6/05/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:SCLP
CUSIP: N/A
CIK: N/A
Web: www.scancell.co.uk
Phone: +44-115-8231863
Fax: N/A
Employees: 25
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): GBX (0.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: £-8,440,000.00
Net Margins: -160.08%
Pretax Margin: N/A
Return on Equity: -44.27%
Return on Assets: -16.31%

Debt

Debt-to-Equity Ratio: 61.41
Current Ratio: 11.45
Quick Ratio: 13.01

Sales & Book Value

Annual Sales: £5.27 million
Price / Sales: 24.07
Cash Flow: GBX 1.97 per share
Price / Cash Flow: 7.86
Book Value: GBX 2 per share
Price / Book: 7.75

Miscellaneous

Outstanding Shares: 818,400,000
Free Float: N/A
Market Cap: £126.85 million
Optionable: Not Optionable
Beta: 0.59

Key Executives

Prof. Lindy Gillian Durrant Ph.D.
Founder, CEO, Chief Scientific Officer & Director

Dr. Sally Elizabeth Adams (Age 61)
Chief Devel. Officer & Director
Comp: $255.65k

Mr. Keith Green
Director of Fin. & Admin. and Company Sec.

Dr. Samantha Paston Ph.D.
Head of Translational Research

Dr. Adrian Parry Ph.D.
Head of Manufacturing

Ms. Akua Asare
Head of Quality

Mr. Fayaz Master
Head of Clinical Operations

Key Competitors

View All Competitors

SCLP Stock - Frequently Asked Questions

How have SCLP shares performed in 2023?: Scancell's stock was trading at GBX 24.75 at the beginning of the year. Since then, SCLP shares have decreased by 37.4% and is now trading at GBX 15.50.
View the best growth stocks for 2023 here.
How were Scancell's earnings last quarter?: Scancell Holdings plc (LON:SCLP) released its quarterly earnings data on Friday, January, 31st. The company reported ($0.56) EPS for the quarter. Scancell had a negative net margin of 160.08% and a negative trailing twelve-month return on equity of 44.27%.
What other stocks do shareholders of Scancell own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Scancell investors own include KAZ Minerals (KAZ), Standard Chartered (STAN), Petropavlovsk (POG), AorTech International (AOR), Ascential (ASCL), Advanced Oncotherapy (AVO), Empyrean Energy (EME), Lloyds Banking Group (LYG), Aminex (AEX) and Sound Energy (SOU).
What is Scancell's stock symbol?: Scancell trades on the London Stock Exchange (LON) under the ticker symbol "SCLP."

How do I buy shares of Scancell?: Shares of SCLP stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is Scancell's stock price today?: One share of SCLP stock can currently be purchased for approximately GBX 15.50.
How much money does Scancell make?: Scancell (LON:SCLP) has a market capitalization of £126.85 million and generates £5.27 million in revenue each year. The company earns £-8,440,000.00 in net income (profit) each year or GBX (0.01) on an earnings per share basis.
How can I contact Scancell?: Scancell's mailing address is Department of Clinical Oncology Hucknall Road, NOTTINGHAM, NG5 1PB, United Kingdom. The official website for the company is www.scancell.co.uk. The company can be reached via phone at +44-115-8231863.

This page (LON:SCLP) was last updated on 6/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial